Review
doi: 10.1016/j.exphem.2007.01.010.
Management of radiation-induced nausea and vomiting
Affiliations
- PMID: 17379085
- DOI: 10.1016/j.exphem.2007.01.010
Item in Clipboard
Review
Management of radiation-induced nausea and vomiting
Exp Hematol.
2007 Apr.
Free article
Abstract
Management of radiation-induced nausea and vomiting (RINV) includes both prevention and therapy. Primary prevention involves implementation of measures to modify risk factors. Secondary prevention involves prophylaxis and treatment with 5HT(3) receptor antagonists (5HT(3)RAs) with or without corticosteroids, dopamine antagonists, antihistamines, or anticholinergics. 5HT(3)RAs are also useful in treatment of RINV with significantly better outcomes, compared to other antiemetics or placebo. Agents include ondansetron, granisetron, dolasetron, palonosetron, and tropisitron. These agents may be useful in both the radiotherapy patient and the individual who has been accidentally exposed to ionizing radiation.
Similar articles
-
Prophylaxis versus treatment: is there a better way to manage radiotherapy-induced nausea and vomiting?Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1018-25. doi: 10.1016/j.ijrobp.2004.07.722. Int J Radiat Oncol Biol Phys. 2004. PMID: 15519770 Review.
-
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.Clin Adv Hematol Oncol. 2004 May;2(5):284-9. Clin Adv Hematol Oncol. 2004. PMID: 16163194 Review.
-
Blueprint for the control of radiation-induced nausea and vomiting. Discussion.Acta Oncol. 2004 Sep;43 Suppl 15:23-4. doi: 10.1080/11001700410016170. Acta Oncol. 2004. PMID: 15370627 No abstract available.
-
5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?Cancer. 2005 Jul 1;104(1):1-18. doi: 10.1002/cncr.21141. Cancer. 2005. PMID: 15929119 Review.
-
5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).J Clin Oncol. 2006 Jul 20;24(21):3458-64. doi: 10.1200/JCO.2005.04.4685. J Clin Oncol. 2006. PMID: 16849762 Clinical Trial.
Cited by
-
One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient.Support Care Cancer. 2009 Jan;17(1):23-32. doi: 10.1007/s00520-008-0445-x. Epub 2008 Jun 5. Support Care Cancer. 2009. PMID: 18528717
-
Ondansetron rapidly dissolving film for the prophylactic treatment of radiation-induced nausea and vomiting-a pilot study.Curr Oncol. 2015 Jun;22(3):199-210. doi: 10.3747/co.22.2395. Curr Oncol. 2015. PMID: 26089719 Free PMC article.
-
Haloperidol for the treatment of nausea and vomiting in palliative care patients.Cochrane Database Syst Rev. 2015 Nov 2;2015(11):CD006271. doi: 10.1002/14651858.CD006271.pub3. Cochrane Database Syst Rev. 2015. PMID: 26524474 Free PMC article.
-
Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron.Endocrine. 2014 May;46(1):131-7. doi: 10.1007/s12020-013-0054-4. Endocrine. 2014. PMID: 24078409
-
Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems.Disaster Med Public Health Prep. 2011 Oct;5(3):183-201. doi: 10.1001/dmp.2011.73. Epub 2011 Oct 10. Disaster Med Public Health Prep. 2011. PMID: 21986999 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
